Düsseldorf, Germany, August 4, 2022 /PR Newswire/ — LenioBio GmbH, a German life sciences biotechnology company providing innovative protein manufacturing technologies, today announced the appointment of Jasper Leink as Chief Business Officer of its leadership team.
In his new role as Chief Business Officer, Mr. Levink will be responsible for driving RenioBio’s business development and business strategy.
“We are thrilled that Jasper Levin has agreed to take on this senior role at LenioBio,” said the CEO. Remberto Martis“We will benefit from Mr. Levink’s extensive expertise in biotechnology business and strategy development. Jasper Levink’s appointment comes at a time when we need to expand our platform and scale our business development efforts.” I came to
Mr. Levink has joined LenioBio. January 2022 As head of the Alternative Proteins business unit, he has focused on advancing LenioBio’s expression platform for applications in alternative protein applications such as cultivated meat and cosmetics. He will continue in this role alongside his new appointment.
“I am inspired by the potential of LenioBio’s ALiCE® technology. I look forward to working with other members of the management team to develop the business towards .”
Mr. Levin brings to LenioBio more than 11 years of experience in business development and strategic consulting in the life sciences and healthcare sectors. Until recently, he held a senior position at his ttopstart BV, helping scientists and companies get funding and build smarter strategies, securing more than €500 million in funding. Levink is also co-founder of a care facility for youth with mental health issues and co-founder of doccs, a Dutch organization that improves GP care.
This new appointment follows the announcement that the company has achieved a significant milestone by successfully scaling its cell-free protein synthesis platform, ALiCE®, to industrial scale.
For more information on the LenioBio Leadership Team, please visit www.leniobio.com/team.
LenioBio is a protein expression platform company committed to advancing innovative technologies for protein discovery, development, and large-scale production beyond the limits of the cell.
LenioBio was incorporated as a legal entity. Germany of September 2016with office Dusseldorf R&D and production lab in Aachen. For more information, visit Leniobio.com and follow LenioBio on LinkedIn.
Logo – https://mma.prnewswire.com/media/1758134/LenioBio_Logo.jpg
Source LenioBio GmbH